NASDAQ:ERNA Ernexa Therapeutics Q1 2026 Earnings Report $6.97 -0.43 (-5.81%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$6.82 -0.15 (-2.08%) As of 06/26/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ernexa Therapeutics EPS ResultsActual EPS-$6.95Consensus EPS -$1.95Beat/MissMissed by -$5.00One Year Ago EPSN/AErnexa Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AErnexa Therapeutics Announcement DetailsQuarterQ1 2026Date5/11/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsErnexa Therapeutics' next earnings date is estimated for Wednesday, August 12, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Ernexa Therapeutics Earnings HeadlinesErnexa Therapeutics (NASDAQ:ERNA) Raised to Hold at Wall Street ZenJune 27 at 1:24 AM | americanbankingnews.comErnexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for PatientsJune 25 at 9:15 AM | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Ernexa Therapeutics Inc.: Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in ...June 17, 2026 | finanznachrichten.deErnexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human StudyJune 17, 2026 | globenewswire.comErnexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring ...June 9, 2026 | markets.businessinsider.comSee More Ernexa Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ernexa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ernexa Therapeutics and other key companies, straight to your email. Email Address About Ernexa TherapeuticsEterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.View Ernexa Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneFabrinet Is Becoming a Quiet Winner in the AI Optics BuildoutMicron’s HBM Surge Could Redefine the AI Growth StoryCarnival's Second Quarter: Is the Stock Still Complicated?Xcel Energy Stock Offers Stability as Electricity Demand BuildsThis Single Factor Is Holding Back Carvana’s Disruptive EdgePaychex Stock Looks Beaten Down, But Not Broken Upcoming Earnings NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
